Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYCC shares. View CYCC analyst ratings or view top-rated stocks .

What is Cyclacel Pharmaceuticals' stock price target for 2024?

2 analysts have issued twelve-month price targets for Cyclacel Pharmaceuticals' shares. Their CYCC share price targets range from $21.00 to $21.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,073.2% from the stock's current price. View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts .

How have CYCC shares performed in 2024?

Cyclacel Pharmaceuticals' stock was trading at $2.67 at the start of the year. Since then, CYCC stock has decreased by 33.0% and is now trading at $1.79. View the best growth stocks for 2024 here .

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 24,300 shares, a decrease of 8.6% from the March 15th total of 26,600 shares. Based on an average daily trading volume, of 145,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.0% of the shares of the company are short sold. View Cyclacel Pharmaceuticals' Short Interest .

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CYCC earnings forecast .

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings results on Tuesday, March, 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, beating analysts' consensus estimates of ($6.35) by $0.12. The biotechnology company had revenue of $0.03 million for the quarter.

When did Cyclacel Pharmaceuticals' stock split?

Shares of Cyclacel Pharmaceuticals reverse split on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com . Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , NVIDIA (NVDA) , Novavax (NVAX) , Gilead Sciences (GILD) , Heat Biologics (HTBX) , McEwen Mining (MUX) and Tesla (TSLA) .

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CYCC Stock Alerts

$1.79

-0.06 (-3.24%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.77
▼
$1.95
50-Day Range: $1.58
▼
$2.97
52-Week Range: $1.52
▼
$13.20

Volume: 10,326 shs
Average Volume: 131,945 shs
Market Capitalization: $2.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get Cyclacel Pharmaceuticals alerts:

Cyclacel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,073.2% Upside
$21.00 Price Target
Short Interest: Healthy
2.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($18.70) to ($3.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Cyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Cyclacel Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.03% of the float of Cyclacel Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cyclacel Pharmaceuticals has recently decreased by 8.65%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cyclacel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYCC.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.47% of the stock of Cyclacel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($18.70) to ($3.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cyclacel Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cyclacel Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cyclacel Pharmaceuticals has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CYCC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYCC Stock News Headlines

April 16, 2024 | americanbankingnews.com

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

April 1, 2024 | globenewswire.com

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 27, 2024 | money.usnews.com

Cyclacel Pharmaceuticals Inc

March 21, 2024 | seekingalpha.com

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

March 20, 2024 | finance.yahoo.com

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript

March 19, 2024 | msn.com

CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023

March 19, 2024 | globenewswire.com

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 13, 2024 | globenewswire.com

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | globenewswire.com

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 6, 2024 | globenewswire.com

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

February 22, 2024 | finance.yahoo.com

Cyclacel Pharmaceuticals, Inc. (CYCCP)

February 20, 2024 | globenewswire.com

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

February 15, 2024 | finance.yahoo.com

Cyclacel Pharmaceuticals Inc. (UXI.SG)

January 8, 2024 | finance.yahoo.com

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

December 22, 2023 | msn.com

Why Cyclacel Pharmaceuticals (CYCC) Shares Are Getting Obliterated

December 22, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

December 20, 2023 | msn.com

Brookline Capital Downgrades Cyclacel Pharmaceuticals (CYCC)

December 15, 2023 | benzinga.com

Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Dividends: History, Yield and Dates

December 12, 2023 | finance.yahoo.com

Cyclacel Pharmaceuticals Announces Reverse Stock Split

November 30, 2023 | msn.com

Cyclacel Pharmaceuticals regains compliance with Nasdaq listing rules

November 28, 2023 | benzinga.com

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

November 28, 2023 | finance.yahoo.com

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

November 27, 2023 | msn.com

Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94

November 24, 2023 | morningstar.com

Cyclacel Pharmaceuticals Inc CYCC

October 19, 2023 | msn.com

Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% goes ex dividend tomorrow

See More Headlines

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CYCC
CUSIP: N/A
CIK: 1130166
Web: www.cyclacel.com
Phone: (908) 517-7330
Fax: 866-271-3466
Employees: 2,018
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $21.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +1,060.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($27.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,560,000.00
Net Margins: N/A
Pretax Margin: -6,083.57%
Return on Equity: -448.19%
Return on Assets: -151.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.91
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $420,000.00
Price / Sales: 5.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.57 per share
Price / Book: 3.18

Miscellaneous

Outstanding Shares: 1,318,000
Free Float: 1,206,000
Market Cap: $2.39 million
Optionable: Optionable
Beta: 0.54

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Spiro George Rombotis (Age 65)
President, CEO & Executive Director
Comp: $612.47k
Mr. Paul McBarron (Age 63)
Executive VP of Finance, CFO, COO, Secretary & Executive Director
Comp: $321.61k
Grace Kim
Investor Relations Executive

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CYCC Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYCC shares.
View CYCC analyst ratings or view top-rated stocks.
What is Cyclacel Pharmaceuticals' stock price target for 2024?: 2 analysts have issued twelve-month price targets for Cyclacel Pharmaceuticals' shares. Their CYCC share price targets range from $21.00 to $21.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,073.2% from the stock's current price.
View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts.
How have CYCC shares performed in 2024?: Cyclacel Pharmaceuticals' stock was trading at $2.67 at the start of the year. Since then, CYCC stock has decreased by 33.0% and is now trading at $1.79.
View the best growth stocks for 2024 here.
Are investors shorting Cyclacel Pharmaceuticals?: Cyclacel Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 24,300 shares, a decrease of 8.6% from the March 15th total of 26,600 shares. Based on an average daily trading volume, of 145,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.0% of the shares of the company are short sold.
View Cyclacel Pharmaceuticals' Short Interest.
When is Cyclacel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CYCC earnings forecast.
How were Cyclacel Pharmaceuticals' earnings last quarter?: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings results on Tuesday, March, 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, beating analysts' consensus estimates of ($6.35) by $0.12. The biotechnology company had revenue of $0.03 million for the quarter.

When did Cyclacel Pharmaceuticals' stock split?: Shares of Cyclacel Pharmaceuticals reverse split on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?: 1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cyclacel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).
How do I buy shares of Cyclacel Pharmaceuticals?: Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYCC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial